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Inhibition of the bile salt export pump (BSEP) has been linked to incidence of drug-induced
liver injury (DILI), presumably by the accumulation of toxic bile acids in the liver. We have
previously constructed and validated a model of bile acid disposition within DILIsym®, a
mechanistic model of DILI. In this paper, we use DILIsym® to simulate the DILI response
of the hepatotoxic BSEP inhibitors bosentan and CP-724,714 and the non-hepatotoxic
BSEP inhibitor telmisartan in humans in order to explore whether we can predict that
hepatotoxic BSEP inhibitors can cause bile acid accumulation to reach toxic levels. We also
simulate bosentan in rats in order to illuminate potential reasons behind the lack of toxicity
in rats compared to the toxicity observed in humans. DILIsym® predicts that bosentan,
but not telmisartan, will cause mild hepatocellular ATP decline and serum ALT elevation
in a simulated population of humans. The difference in hepatotoxic potential between
bosentan and telmisartan is consistent with clinical observations. However, DILIsym®
underpredicts the incidence of bosentan toxicity. DILIsym® also predicts that bosentan
will not cause toxicity in a simulated population of rats, and that the difference between
the response to bosentan in rats and in humans is primarily due to the less toxic bile
acid pool in rats. Our simulations also suggest a potential synergistic role for bile acid
accumulation and mitochondrial electron transport chain (ETC) inhibition in producing the
observed toxicity in CP-724,714, and suggest that CP-724,714 metabolites may also play
a role in the observed toxicity. Our work also compares the impact of competitive and
noncompetitive BSEP inhibition for CP-724,714 and demonstrates that noncompetitive
inhibition leads to much greater bile acid accumulation and potential toxicity. Our research
demonstrates the potential for mechanistic modeling to contribute to the understanding
of how bile acid transport inhibitors cause DILI.
Keywords: BSEP inhibition, bile acids and salts, drug-induced liver injury, mechanistic modeling, bosentan,
CP-724,714, population variability
INTRODUCTION
Inhibition of the bile salt export pump (BSEP) by a drug has
been implicated as a risk factor for the drug’s potential to
cause drug-induced liver injury (DILI) (Dawson et al., 2011;
Morgan et al., 2013). Several high-profile DILI-causing drugs,
for example troglitazone (Funk et al., 2001; Smith, 2003), bosen-
tan (Fattinger et al., 2001; Eriksson et al., 2011), and nefazodone
(Kostrubsky et al., 2006), have been shown to be BSEP inhibitors.
Furthermore, prediction of toxicity by these molecules has been
uneven; for example, neither bosentan nor troglitazone displayed
toxicity in animal models (Leslie et al., 2007; Lauer et al., 2009).
Predictions involving hepatobiliary transporter IC50 values in
in vitro assays have shown better predictive ability (Dawson et al.,
2011; Morgan et al., 2013). Improving the ability to predict the
frequency and severity of DILI with BSEP inhibitors will allow
those involved in drug development to better judge the risk
involved with moving a drug in development into the clinic or
beyond early-stage clinical trials.
DILIsym® is a multi-scale mechanistic model incorporating
numerous functions of the liver and disruptions of the function
with the goal of predicting the DILI potential of drugs at vari-
ous stages in the development process (Howell et al., 2012, 2014;
Woodhead et al., 2012; Shoda et al., 2014). Previously, we have
constructed and validated a model of bile acid homeostasis and
transporter inhibition within DILIsym® (Woodhead et al., 2014).
We found that inhibiting BSEP could lead to significant increases
in bile acid concentrations in the liver, and that the effects of
bile acid transporter inhibitors should be considered on a sim-
ulated population as well as on a single baseline individual. We
have expanded that model to include a representation of bile acid-
mediated toxicity based on experiments performed by Yang et al.
(2013). In that work, we constructed a relationship between intra-
cellular bile acid concentration and cellular ATP. We used this
relationship to predict cellular necrosis using the existing rela-
tionship between ATP and cell death in DILIsym®. This model
has been used previously to effectively predict the frequency and
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timing of ALT elevations observed with troglitazone in clinical tri-
als, and has predicted the difference between troglitazone and the
similar non-toxic drug pioglitazone (Yang et al., 2014).
In the present work, we use this model of bile acid-mediated
cytotoxicity to model the observed hepatotoxicity of bosentan,
telmisartan, and CP-724,714. Bosentan is a currently marketed
medication for pulmonary arterial hypertension that carries a
black-box warning for hepatotoxicity. In clinical trials a dose of
1000 mg/day of bosentan caused between 8 and 18% of indi-
viduals to experience increases in serum ALT greater than 3-fold
(Fattinger et al., 2001). Bosentan has also been shown to be a
relatively potent BSEP inhibitor. Telmisartan, an angiotensin II
receptor agonist used in hypertension treatment, is also a rela-
tively potent BSEP inhibitor, but has not been reported to cause
hepatotoxicity in humans (Morgan et al., 2013). CP-724,714 is
an anti-cancer drug that was terminated from development after
Phase II clinical trials revealed liver signals (Guo et al., 2008).
CP-724,714 has been shown to inhibit multiple transporters,
including BSEP, in addition to being a mitochondrial toxin (Feng
et al., 2009). In this report we explore the DILIsym® software’s
(version 2C) predictions for the toxicity of bosentan in humans,
and the lack of toxicity of bosentan in rats and telmisartan in
humans. We will also test several theories about the toxicity of
CP-724,714 in order to suggest potential viable explanations for
the observed toxicity in early clinical trials.
METHODS
The construction and validation of the bile acid homeostasis
model in DILIsym® is described in a previous paper (Woodhead
et al., 2014). DILIsym® models the synthesis and enterohepatic
recirculation of twomain potentially toxic bile acids, chenodeoxy-
cholic acid (CDCA) and lithocholic acid (LCA), and their amide
(and sulfate in the case of LCA) conjugates. DILIsym® describes
the intrahepatic accumulation of these toxic bile acids as well as
the concentrations in the gallbladder, portal blood, gut lumen,
and systemic blood. Concentrations of bile acid transporter
inhibitors are modeled using a physiologically-based pharma-
cokinetic model (PBPK) described in depth in previous papers
(Howell et al., 2012; Woodhead et al., 2012). The bile acid con-
centrations are linked to ATP decline as described below; the
effect of ATP decline on eventual hepatocyte necrosis is described
by a model of the hepatocyte life cycle also described in previ-
ous papers (Howell et al., 2012; Woodhead et al., 2012; Shoda
et al., 2014). A diagram of the interaction between the various
submodels of DILIsym® employed in this paper can be seen in
Figure 1.
The DILIsym® model of bile acid toxicity is based on in vitro
experiments comparing the intracellular level of LCA and CDCA
to cellular ATP levels (Yang et al., 2013). In order to construct the
connection between bile acid accumulation and toxicity, a small
model of the DILIsym® ATP turnover model was constructed
(Yang et al., 2013); a diagram of this model is shown in Figure 2.
The relationship between intracellular ATP and intracellular bile
acids was modeled by the following equation:
d[ATP]
dt
= kusage − ksynthS
where kusage is the rate of ATP usage in the cell, ksynth is the rate
of ATP synthesis in the cell, and S is the signal for ATP synthesis
inhibition by bile acids. S has Hill type behavior and is given by
the following equation:
S = 1
1 + Vmax,S[BA]
H
delay
KHm,S + [BA]Hdelay
where Vmax,S is the maximum denominator for the signal, Km,S
is the Michaelis constant for the signal, and H is the Hill coeffi-
cient for the signal. [BA]delay is the delayed intracellular bile acid
concentration, given by the standard delay equation:
d[BA]delay
dt
= τ ([BA] − [BA]delay)
The delay constant τ , Vmax,S, Km,S, and H were the parameters
that were fitted to the ATP time course from the experiment.
These parameters were then applied to the intracellular bile acid
concentrations modeled in DILIsym®. We applied the parame-
ters for the unconjugated bile acids measured in the experiments
to the conjugated bile acids in DILIsym®; for example, we used
the unconjugated LCA parameters to describe the toxicity of LCA
amide and sulfate conjugates. While some data exist describ-
ing the relationship between intracellular amide- and sulfate-
conjugated bile acids and toxicity (Chatterjee et al., 2013), these
are not enough to justify using different toxicity parameters for
conjugated and unconjugated bile acids; this is an area of potential
refinement for DILIsym®.
Physiologically-based pharmacokinetic (PBPK) models were
constructed for bosentan, telmisartan, and CP-724,714 in
humans using available in vivo time course data (Weber et al.,
1996; Stangier et al., 2000; Munster et al., 2007). For simula-
tions where bosentan metabolism was impaired, the Vmax for the
metabolism of both metabolites was represented as 10% of their
baseline value. Both bosentan and telmisartan are active trans-
port substrates; the active transport parameters for both were
adapted for use in DILIsym® from Ménochet et al. (2012). The
bosentan PBPK model includes the major and minor metabo-
lite, with metabolism parameters based on published in vitro
metabolism data (Ubeaud et al., 1995); these were included
because the minor metabolite of bosentan also inhibits BSEP
(Fattinger et al., 2001). The major metabolite of telmisartan, a
glucuronide, has not been shown to inhibit BSEP and so was not
included in the PBPK model. CP-724,714’s complex metabolism
was not modeled explicitly; however, a single metabolite com-
partment in the liver was included in order to test the hypothesis
of whether metabolite accumulation could explain CP-724,714
toxicity. PBPK model results for human bosentan are shown in
Figure 3; those for human telmisartan are shown in Figure 4; and
those for human CP-724,714 in Figure 5. For bosentan in rats,
data did not exist in the literature. Data provided to us from
Amgen, Inc. (Thousand Oaks, CA) were used to parameterize the
bosentan rat PBPK model shown in Figure 6.
Inhibition constants for bosentan were taken from published
research that found Ki values for both bosentan (12µM) and the
minor metabolite of bosentan (8.5µM) (Fattinger et al., 2001).
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FIGURE 1 | Partial diagram of the portions of DILIsym® used for this paper, including the PBPK representation, representation of bile acid
homeostasis and accumulation, link between bile acid concentrations and toxicity, and the hepatocyte life cycle.
www.frontiersin.org November 2014 | Volume 5 | Article 240 | 3
Woodhead et al. Mechanistic model of DILI from BSEP inhibition
FIGURE 2 | Diagram of the model of ATP turnover used to parameterize
the hepatocellular toxic response to accumulation of bile acids. The
model was set up to accept the experimentally measured intracellular
concentration of each bile acid, and parameters were fit to the model in
order to fit the experimentally observed intracellular ATP levels for each bile
acid exposure.
FIGURE 3 | Simulated plasma concentration of bosentan in humans
and its two metabolites after a 500mg oral dose compared to data
from Weber et al. (1996).
The inhibition of BSEP by bosentan and its metabolite were mod-
eled as noncompetitive in agreement with the data. These data
are from rat Bsep vesicles; we assigned the same Ki value to
humans, as there is evidence suggesting that rat Bsep and human
BSEP are inhibited with similar potency by bosentan (Mano et al.,
2007). Bile acid uptake inhibition constants for bosentan were
taken from work done by Leslie et al. (2007). The telmisartan Ki
was approximated using the IC50 value reported in the literature
(Morgan et al., 2013). A list of Ki values used in our simulations
is included in Table 1. In addition, bosentan is a potent inducer
of its own uptake into the liver and metabolism (Dingemanse and
van Giersbergen, 2004); these effects are included in our PBPK
model. It is important to note that for each drug, only the param-
eters related to drug pharmacokinetics and transporter inhibition
FIGURE 4 | Simulated plasma telmisartan concentration in humans
after a single 80mg oral dose compared to data from Stangier et al.
(2000).
were changed; all other remaining parameters were not changed
from drug to drug.
For CP-724,714 IC50 values, experiments were run in rat Bsep,
dog Bsep, and human BSEP-expressing vesicles. CP-724,714 was
synthesized by Pfizer, Inc. (Groton, CT), while radiochemicals
were purchased from Perkin Elmer (Perkin Elmer, WalthamMA).
Other chemicals were purchased from Sigma-Aldrich (Sigma-
Aldrich, St Louis, MO) or were of analytical grade. Membrane
vesicles were obtained from Sf9 cells not expressing and express-
ing human BSEP (Solvo Biotechnology, Szeged, Hungary), rat
Bsep (AB Life Technologies, Waltham, MA), or dog Bsep (AB Life
Technologies).
CP-724,714 was incubated (2 or 5min) with membrane vesicle
preparations (total protein: 50µg/well) and the probe substrate,
taurocholate (2µM). Serial dilutions of CP-724,714 (30mM
stock, 10mM, 3.16mM, 1mM, 316µM, 100µM, 31.6µM,
10µM) were prepared in DMSO. Incubations in duplicate were
carried out in the absence or presence of 4mM ATP to dis-
tinguish between transporter mediated uptake and passive dif-
fusion into the vesicles. CP-724,714 was added to the reaction
mixture in 0.75µl of solvent (1% of the final incubation vol-
ume). Glyburide (100 – 0.1µM) was used as the positive control
inhibitor. Reaction mixtures were pre-incubated for 10min at
37◦C. Reactions were started by the addition of 25µl of 12mM
MgATP (or AMP, as disodium salt, for background controls), pre-
incubated separately. Reactions were stopped by the addition of
200µl of ice-cold washing buffer and immediate filtration via
glass fiber filters mounted to a 96-well plate (filter plate). The
filters were washed, dried and the amount of substrate inside
the filtered vesicles determined by liquid scintillation. Maximal
observed inhibition ranged between 94.8 and 99.8% for CP-
724,714. Further information on this method can be found in the
literature (Kis et al., 2009).
Bosentan dosing in humans was simulated as a 500-mg twice-
daily dose for 30 days. The doses were given once every 12 h; this is
one of the dosing regimens in the clinical trials that demonstrated
toxicity as reported by Fattinger et al. (2001). Telmisartan dosing
was simulated as a 50, 3000, or 12,000-mg dose once daily for 30
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FIGURE 5 | Simulated plasma human concentrations of CP-724,714 after an oral dose of 250mg (A) and 400mg (B) compared to data from Munster
et al. (2007). The 250mg dose data represented in this figure are a compilation of the results from the first dose of several different dosing protocols.
FIGURE 6 | Simulated plasma bosentan concentrations in rats after an intravenous oral dose of 10mg (A), 30mg (B), and 100mg (C) compared to
data provided by Amgen, Inc. (Thousand Oaks, CA).
days; common clinical dosing regimens range from 40 to 80mg
per day (Meredith, 1999). CP-724,714 was dosed three times daily,
or once every 8 h. A range of CP-724,714 doses were simulated
in order to cover the range of exposure levels reported by Guo
et al. (2008). Three simulated meals per day were included in all
human simulations, and simulated to occur concurrent with drug
dosing. Bosentan dosing in rats was simulated as a 50mg/kg dose
once daily.
DILIsym® contains simulated populations, or SimPops™, that
represent a plausible range of variability in key model parameters.
The human SimPops™ and rat SimPops™ used in the course of
these simulations contain variability in several bile acid transport
parameters and are described in our previous work (Woodhead
et al., 2014; Yang et al., 2014). There are 331 individuals in the
human SimPops™ and 191 individuals in the rat SimPops™;
although the numbers of individuals are different, both the
human and the rat SimPops™ are designed to account for the
entire plausible range in variability in bile acid transport param-
eters and bile acid profiles observed in a sample population
(Woodhead et al., 2014). Pharmacokinetic variability in bosentan
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disposition was also included in one SimPops™ simulation; for
this population, a normal distribution around four variables (oral
absorption coefficient, liver uptake Vmax, and major and minor
metabolite formation Vmax) was superimposed upon the exist-
ing small human SimPops™. The range of these parameter values
was based on a known range of variability for hepatobiliary trans-
porters (Meier et al., 2006) and upon previous simulations where
pharmacokinetic variability was considered (Woodhead et al.,
2012).
RESULTS
Results from the SimPops™ analysis with bosentan are presented
in Table 2. When we simulated bosentan in the human SimPops™
using the baseline assumptions (noncompetitive inhibition, no
basolateral inhibition, normal metabolism), 1 individual out of
331 developed ALT elevations greater than 3-fold above the base-
line value. When potential variability in pharmacokinetics was
incorporated into the SimPops™, the predicted incidence rate
rose to 3 out of 331. While this successfully predicts the potential
toxicity of bosentan, the incidence rate is well below the incidence
rate of 8–18% observed during the clinical trials (Fattinger et al.,
2001).
A genetic polymorphism that limits CYP metabolism has been
shown to correlate with an increased rate of toxicity from bosen-
tan exposure (Markova et al., 2013). We have simulated this
case using the human SimPops™ by decreasing the bosentan
metabolismVmax values for bothminor andmajor metabolites by
10-fold. This change led to eight simulated individuals out of 331
(2.42%) developing ALT elevations. DILIsym® correctly predicts
the increased risk of toxicity due to this potential genetic poly-
morphism, though the predicted incidence rate is still less than
the overall rate in the general population from the clinical study.
When bosentan was also simulated in the rat SimPops™, zero
individual rats out of 191 developed ALT elevations. This is
consistent with preclinical observations which have reported no
toxicity in the rat (Leslie et al., 2007). It has been suggested that
the difference in bile acid uptake inhibition by bosentan between
rats and humans contributes to the species difference in hepato-
toxicity (Ansede et al., 2010). In order to test this theory, we ran
a simulation in the rat SimPops™ with uptake inhibition elimi-
nated (Ki set to 1 × 1010); though bile acid accumulation in the
liver was predicted (results not shown), no toxicity was observed.
This suggests that the difference in the bile acid pool between
humans and rats is likely a more significant contributor to the
species difference in toxicity.
In order to ensure that the model can differentiate non-toxic
BSEP inhibitors from toxic BSEP inhibitors, we modeled telmis-
artan in the human SimPops™. No toxicity was predicted in the
human SimPops™, which is consistent with clinical observations.
This was true whether telmisartan was modeled as a competitive
or a noncompetitive inhibitor.
While there is scant difference between predicting one individ-
ual developing toxicity and predicting zero individuals developing
toxicity (out of 331), a fuller understanding of the risk of a given
compound can be gained by investigating more mechanistic data
within DILIsym®. Figure 7 displays the minimum hepatic ATP
for each individual in the human and rat SimPops™ for bosen-
tan and the human SimPops™ for telmisartan (modeled as both a
competitive and non-competitive inhibitor of BSEP). We can see
that while only one simulated individual in the human SimPops™
had an ATP decline after bosentan dosing that ultimately led to
toxicity, manymore had ATP reductions visibly below the baseline
value. This was not true of the rat, or of telmisartan in either case;
the simulated individuals all have hepatic ATP values very close
to the baseline value. This places the difference between bosen-
tan and telmisartan, and the difference between rat and human,
in sharper relief and demonstrates the potential of the model
for predicting species differences in toxicity and differentiating
between toxic and non-toxic BSEP inhibitors.
The simulation results for CP-724,714 in the baseline human
individual, and a comparison of these results to the clinical obser-
vations in Guo et al. (2008), are shown in Figure 8. The graph
compares the normalized liver function test (LFT) elevation
Table 2 | SimPops™ simulation results for simulated ALT elevations
caused by bosentan and telmisartan.
SimPops simulation Number of Percentage
ALT > 3×
Bosentan – baseline 1 0.302%
Bosentan – PK/toxicity variability 3 0.906%
Bosentan – 10× lower metabolism 8 2.42%
Bosentan – basolateral transporter inhibition 4 1.21%
Bosentan – rat 0 0
Telmisartan – competitive 0 0
Telmisartan – noncompetitive, 50mg/day 0 0
Telmisartan – noncompetitive, 3000mg/day 0 0
Telmisartan – noncompetitive, 12,000mg/day 1 0.302%
Table 1 | Inhibition constants used for the compounds in the simulations conducted for this paper.
Compound Species Transporter Ki Mode References
Bosentan Rat BSEP 12µM Noncompetitive Fattinger et al., 2001
Bosentan minor metabolite Rat BSEP 8.5µM Noncompetitive Fattinger et al., 2001
Bosentan Rat NTCP 0.23µM Noncompetitive Leslie et al., 2007
Bosentan Human NTCP 18µM Competitive Leslie et al., 2007
Telmisartan Human BSEP 16µM* N/A Morgan et al., 2013
CP-724,714 Human BSEP 7.45µM* N/A Novel data
*Denotes that the Ki was approximated using the listed IC50 value for which mode of inhibition was not determined.
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FIGURE 7 | ATP levels in individuals after simulated dosing of bosentan to
the human SimPops™ (A) and the rat SimPops™ (B); and with simulated
telmisartan dosing to the human SimPops™ when represented as a
competitive (C) and noncompetitive (D) inhibitor. Each point represents an
individual within the human SimPops™; the baseline ATP concentration in
humans is 4.2mM, while in rats the baseline ATP concentration is 2.0mM.
FIGURE 8 | Normalized LFT elevation at increasing exposure as
measured by AUC0-24 on Day 1 of Cycle 2 (Day 22 overall) in the
baseline human in DILIsym® and the clinical trial patients from Guo
et al. (2008). The lines refer to the dose response simulated in DILIsym®
under various assumed conditions listed in the table legend. “Baseline
assumptions” refers to the case where only the parent CP-724,714 inhibits
BSEP competitively and does not inhibit the electron transport chain (ETC).
“Metabolite inhibition” refers to the case where the metabolite of
CP-724,714 inhibits BSEP with the same Ki as the parent compound.
“Poor clearance” refers to the case where the metabolite biliary clearance
value is set to a value 10-fold lower than the parent biliary clearance value.
“Noncompetitive” refers to the case where all BSEP inhibition is modeled
as noncompetitive. “Added ETC inhibition” refers to the case where
inhibition of the electron transport chain was simulated for both parent and
metabolite. The points are individual patients from Guo et al. (2008). The
purple dashes are the individuals in a human SimPops™.
against the AUC of the drug in the patient’s bloodstream on Day
22 (Day 1 of Cycle 2) of drug dosing, a measure of steady-state
drug exposure. The normalized LFT elevation used by the Guo
et al. (2008) paper to which our simulations are compared is given
by the following expression (Guo et al., 2008):
max
(
ALT fold increase
5
,
bilirubin fold increase
3
)
The simulation results are the maximum normalized LFT eleva-
tion at each dose simulated for each individual case. The graph
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shows that bile acid inhibition alone cannot explain the clinical
toxicity, as liver function tests did not elevate in the simulations
when bile acid inhibition alone was simulated. This was true for
both competitive and noncompetitive inhibition. However, the
inclusion of mitochondrial toxicity did, in fact, lead to a toxic
response that was augmented when bile acid accumulation also
occurred. The data are best described here by this combination
of competitive inhibition and electron transport chain (ETC)
inhibition.
The simulations also predict that both BSEP and mitochon-
drial ETC inhibition by CP-724,714’s major metabolite are nec-
essary to explain the toxicity, since CP-724,714 is rather rapidly
metabolized by the liver and so parent residence time within
the liver is somewhat limited. When the potential activity of
the metabolite is not included, no toxicity is shown no mat-
ter the mechanism or combination of mechanisms selected. The
accumulation of this metabolite is also necessary to explain
the toxicity; a biliary clearance of 10% of the value for the
parent compound was used in order to reproduce the clinical
toxicity.
SimPops™ results for CP-724,714 in humans are also shown
in Figure 8, with each individual in the SimPops™ represented by
a purple dash. We found that while the simulated baseline indi-
vidual did not display the toxicity that would have been expected
from the clinical data, the population sample did contain several
individuals who developed clinically-relevant ALT elevations, but
only if the BSEP inhibition was noncompetitive. Furthermore,
the range of injury in the SimPops™ is far wider than the range
reported in the clinical study; the most severe normalized LFT
elevation in our simulated population was 6.5, while the largest
clinical normalized LFT in that exposure range was about 2.
Twelve individuals in our 331-individual SimPops™, or 3.62%,
developed toxicity; this is lower than the 36% of individuals in the
exposure range near the simulated dose who developed LFT ele-
vations. No individuals in the SimPops™ developed toxicity if the
inhibition was competitive, demonstrating the importance of dif-
ferentiating betweenmodes of inhibition when determining BSEP
inhibition constants.
Uncertainty about the biliary clearance of the CP-724,714
metabolite has an impact on simulated ALT elevations. Figure 9
shows simulated ALT elevations at a constant dose of CP-724,714
when the biliary clearance of the metabolite is modulated. This
variable does not affect the plasma pharmacokinetics of parent
CP-724,714; it is thus a degree of freedom in DILIsym®. However,
as Figure 9 shows, it has a significant effect on the predicted toxic-
ity of CP-724,714; DILIsym® suggests, therefore, that experiments
clarifying the amount of hepatic accumulation and clearance of
CP-724,714’s major metabolite should be conducted in order to
fully elucidate the molecule’s toxicity.
DISCUSSION
We have used DILIsym® to model bosentan and found that,
using the mechanistic simulation results calculating ATP decline,
DILIsym® suggests that the potential for toxicity in a human pop-
ulation is greater than that in a rat population. Furthermore,
the same ATP decline simulation results show a clear differ-
ence between the human population response to bosentan and
FIGURE 9 | ALT elevations at different values of metabolite biliary
clearance given competitive BSEP inhibition and ETC inhibition. The
“poor clearance” cases explored in Figure 8 are represented here by the
biliary clearance value of 5mL/h/kg0.75.
to telmisartan. While the prediction of the toxic potential of
bosentan was well below the actual clinical incidence rate, these
results nevertheless show promise for the ability to use a mech-
anistic mathematical model of DILI, rather than small-animal
models, to predict the human toxicity of a BSEP inhibitor. More
revealingly, the modeling exercise suggested a potential reason for
this discrepancy in toxicity between rats and humans. Previous
work in this area demonstrated the difference in uptake trans-
porter inhibition between rats and humans (Leslie et al., 2007;
Ansede et al., 2010) and proposed that this was a contributing
factor to the species difference. However, our simulations suggest
that removing the uptake inhibition from the rat model altogether
does not lead to liver toxicity in the rat. This suggests that the dif-
ference in bile acid pools and metabolic pathways are most likely
the strongest contributor to the species difference in toxicity. The
rat bile acid pool has more non-toxic bile acids, such as cholic
acid and muricholic acid, and less of the toxic bile acids CDCA
and LCA than the human (Hofmann, 2009; García-Cañaveras
et al., 2012). Furthermore, the rat can hydroxylate LCA into the
less-toxic hyodeoxycholic acid, which is a pathway that does not
occur in the human (Hofmann, 2004). Because of these species
differences in bile acid metabolism, our modeling questions the
utility of current small-animal models in the prediction of BSEP
inhibitor-mediated toxicity in humans.
Our results comparing the ATP decrement in the liver caused
by bosentan and telmisartan demonstrate that DILIsym® can dif-
ferentiate between a toxic and a non-toxic compound with a
similar IC50. In the case of bosentan and telmisartan, the dif-
ference is mostly a pharmacokinetic one; telmisartan is dosed
at a far lower dose than is bosentan. However, our results with
increasing telmisartan dose suggest that a much higher dose of
telmisartan, compared to bosentan, is necessary to cause toxi-
city in a human SimPops™. The suggestion is that dose is not
necessarily predictive on its own; differences in metabolism and
in liver uptake transporter affinity and capacity both are likely
contributors to the differences in toxicity between bosentan and
telmisartan.
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While we qualitatively predict the species difference in bosen-
tan toxicity and the toxicity of bosentan compared with the safety
of telmisartan, we substantially underpredict the incidence rate of
the toxicity of bosentan in the general population. Clinical trials
predict 8–18% toxicity at the 1000mg/day dosing level; DILIsym®
predicted amuch lower incidence rate even when individuals with
metabolic polymorphisms were considered.
There are several possible reasons for this discrepancy, mostly
related to the possibility of other mechanisms of toxicity not
currently included in the DILIsym® model of bosentan. First,
we do not represent the inhibition of basolateral bile acid
transport by bosentan; this could prevent a potential clearance
pathway for toxic bile acid species and lead to more toxicity.
Recent research has shown that bosentan has the potential to
inhibit MRP4, a basolateral bile acid transporter (Morgan et al.,
2013). Exploratory simulations representing bosentan as a baso-
lateral transporter inhibitor (reported in Table 2) suggest that
this explanation is likely only part of the problem; if the bosen-
tan basolateral transporter Ki is particularly low, however, this
could account for some of the discrepancy in predicted incidence
rates.
Second, DILIsym® does not represent bile acid toxicity in a
mechanistic manner. Recent research suggests that the bile acids
affect the mitochondria and potentially lead to the mitochondrial
membrane permeability transition (Schulz et al., 2013); repre-
senting this effect in DILIsym® could introduce extra sources of
variability and could lead to a higher predicted toxicity incidence
rate. Indeed, work is underway in this area for DILIsym® and
preliminary results suggest that the mechanistic model increases
the predicted rate of bosentan toxicity without predicting tox-
icity in the rat; this work will be the focus of a subsequent
paper.
Third, bosentan could cause toxicity through mechanisms
not currently included in the model for bosentan or not cur-
rently represented in DILIsym®. Bosentan has been shown to
inhibit phospholipid transport in rodents (Fouassier et al., 2002).
Phospholipids protect the bile duct from the cytotoxic effect of
bile acids; inhibition of phospholipid transport has been shown to
lead to liver toxicity in the case of itraconazole (Yoshikado et al.,
2011). While bosentan’s mechanism of action is dissimilar to that
of itraconazole, this shows that the ability of bosentan to interfere
with phospholipid transport could be at least partially responsi-
ble for the observed toxicity of bosentan. Phospholipid transport
and the toxic effect of its inhibition are not currently represented
in DILIsym®; this is an area for potential future research and
refinement.
Also, bosentan’s effects on the mitochondria have not been
elucidated. Previous research has shown that there is a corre-
lation between the ability to inhibit BSEP and toxic effects on
the mitochondria, and that this combined effect is itself cor-
related with DILI risk (Aleo et al., 2014). Furthermore, our
simulations with CP-724,714 demonstrated that the toxicity seen
in the clinic could not be explained without representing the
drug’s mitochondrial effects; while our research suggests that it
is plausible that a compound could cause toxicity through bile
acid transporter inhibition alone, it is also plausible that the
toxicity of bosentan is due to a combined mitochondria/bile
acid toxicity mechanism. Indeed, our modeling showed that
this was most likely the case with CP-724,714. Research in this
area is underway in our group and will focus on potential syn-
ergy between mitochondrial toxicity and bile acid buildup in
the liver.
Fourth, DILIsym® does not represent the intracellular traffick-
ing and potential localization of the drug within the hepatocyte.
Further research in this area could help us improve DILIsym® and
thus our prediction of toxicity incidence rates.
Our simulations with CP-724,714 demonstrate the abil-
ity of mechanistic modeling to consider and prioritize mul-
tiple hypotheses when modeling compounds where the cause
of toxicity is not fully established. Potential variability in the
degree of hepatic accumulation of a compound that inhibits
BSEP is particularly important, as shown by Figure 9. This is
an especially salient point to consider given that the toxicity
of compounds such as troglitazone are suspected to be due
to the hepatic accumulation of a BSEP-inhibiting metabolite
(Masubuchi, 2006). Furthermore, the difference between compet-
itive and non-competitive inhibition, the potential contribution
of ETC inhibition to the observed toxicity, and the toxic poten-
tial of CP-724,714’s metabolites are all sources of uncertainty that
required a hypothesis-based approach to modeling. While this is
of limited value for predicting toxicity on its own, the hypothesis-
based modeling approach is potentially valuable in determin-
ing which experiments would be most impactful in using the
model to properly predict toxicity. In the case of CP-724,714,
these experiments include hepatic accumulation studies, BSEP
inhibition studies, and ETC inhibition studies on CP-724,714’s
metabolites.
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